Conference: Certis Oncology CEO Presents at 24th Annual Precision World Medicine
Certis Oncology Solutions, a leader in precision oncology and translational science, recently showcased its groundbreaking advancements in artificial intelligence (AI) and machine learning (AI/ML) at the 24th Annual Precision World Medicine Conference in Santa Clara, California. The company’s President and CEO, Peter Ellman, presented a talk titled “Predictive Oncology Intelligence: Revolutionizing Cancer Research with AI-Enabled Precision Oncology,” focusing on the transformative impact of AI/ML in cancer therapeutics and drug development.
Ellman’s presentation centered on Certis Oncology’s proprietary platform, CertisAI™, which plays a critical role in closing the translation gap between preclinical research and clinical trials in cancer drug development. CertisAI™ helps in predicting drug responses, enhancing biomarker strategies, and enabling more informed, data-driven decision-making. In his talk, Ellman highlighted the continued challenges in cancer treatment development, despite the vast amounts of molecular data now available.
“We’ve been talking about personalized medicine for decades, but progress for patients has been limited,” Ellman explained. “Nine out of ten investigational cancer therapies fail in clinical trials. Even with all we now know about cancer at the molecular level, fewer than 10% of patients experience meaningful clinical benefits from genomics-informed treatments. But in 2025, we now have the tools to change that. The combination of advanced computational algorithms and faster, more affordable computing is revolutionizing drug development and how we think about individualized care for patients.”
As part of his presentation, Ellman introduced conference attendees to CertisOI Assistant™, a newly launched generative AI tool that enhances research workflows. This tool makes the evaluation of complex datasets more accessible, helping to democratize research and accelerate the analysis of cancer research models. CertisOI Assistant serves as a natural language intermediary, allowing researchers to more easily analyze genomic data and drug sensitivity information from numerous cancer research models. This includes Certis’ proprietary patient-derived xenograft (PDX) models as well as publicly available cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE).
The AI-driven platform works by predicting therapeutic efficacy based on complex gene expression signatures. CertisAI™ enables researchers to identify how a tumor’s unique genetic profile can influence the response to specific drugs. This technology empowers pharmaceutical researchers to make more accurate decisions when developing new cancer treatments, and provides clinicians with an important tool to identify potential therapeutic options tailored to a patient’s cancer.
CertisAI™: Revolutionizing Cancer Treatment Development
CertisAI™ is a patent-pending AI/ML platform designed to provide accurate predictions of therapeutic efficacy in cancer treatment. The platform’s key differentiator is its ability to identify complex gene expression patterns that correlate with a tumor’s response to various drugs, providing predictive insights that are critical in both drug discovery and clinical care. By identifying these patterns, CertisAI™ helps bridge the gap between preclinical findings and clinical trials, making it a powerful tool in the fight against cancer.
This innovative platform enables precision oncology researchers and clinicians to develop new treatment options for specific cancer types. By analyzing data from a variety of models—including Certis’ own PDX models and the CCLE database—CertisAI™ is able to predict how different tumors may respond to specific drug treatments, facilitating more personalized and effective treatment plans.
Certis Oncology Solutions: Pioneering Precision Oncology
Founded in 2016, Certis Oncology Solutions is a life science technology company committed to realizing the potential of precision oncology. Through its product, Oncology Intelligence®, Certis provides highly predictive therapeutic response data that assists clinicians and researchers in making informed decisions about cancer treatment. The company focuses on bridging the translation gap between preclinical studies and clinical trials, helping to bring precision oncology into mainstream medical practice.
Certis partners with physician-scientists, academic researchers, and industry leaders to expand access to precision oncology and help accelerate the development of new cancer treatments. Their advanced models of cancer, combined with AI-powered insights, offer highly relevant data that helps to determine the most effective treatment strategies for individual patients.
The company’s AI/ML platform, along with its use of patient-derived tumor models, enables Certis to provide clearer evidence of drug efficacy, allowing pharmaceutical companies to make more confident decisions in their drug development processes. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory located in Sorrento Valley, San Diego, which is at the heart of the life sciences industry.
Since its founding, Certis has been at the forefront of personalized cancer treatment testing, offering functional testing to inform individualized treatment decisions. This approach has been embraced by oncology clinicians and researchers globally, further solidifying Certis as a leader in advancing precision medicine for cancer patients.
By combining the power of AI/ML and clinically relevant, patient-derived tumor models, Certis Oncology Solutions is transforming the way cancer research is conducted, ensuring that drug development becomes more efficient, personalized, and ultimately more successful in delivering life-saving therapies. Through these innovations, Certis is working to make meaningful progress in the battle against cancer, one patient at a time.
